Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y).
Adequate rises of vWF:activity and satisfactory haemostasis have been obtained in six von Willebrand patients treated with heated 8Y factor VIII concentrate, despite multimeric analysis showing the concentrate to have an alteration in the proportions of the different vWF:Ag multimers including slight loss of the highest molecular weight multimers and an abnormal triplet. As heat-treated concentrates reduce the risk of transmitting blood borne viruses 8Y concentrate should be considered as a possible first line treatment of vWD patients in the U.K. if they do not have mild forms of type I von Willebrand's disease which can be treated with desmopressin (DDAVP) infusions.
Pasi
K J
KJ
Department of Haematology, Children's Hospital, Ladywood, Birmingham.
Williams
M D
MD
Enayat
M S
MS
Hill
F G
FG
D000293:Adolescent; D000328:Adult; D000941:Antigens / Q000032:analysis / Q000378:metabolism; D002648:Child; D005169:Factor VIII / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006358:Hot Temperature; D006801:Humans; D008297:Male; D008970:Molecular Weight; D014842:von Willebrand Diseases / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D014841:von Willebrand Factor / Q000378:metabolism
D000941:Antigens; C029417:Von Willebrand antigen; D014841:von Willebrand Factor; D005169:Factor VIII